open access

Vol 79, No 2 (2008)
ARTICLES
Get Citation

CA 125 regression after two cycles of neoadjuvant chemiotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction

Włodzimierz Baranowski, Cezary Szczylik, Małgorzata M. Jerzak, Gabriel B. Wcisło, Agnieszka Gąsowska-Bodnar
Ginekol Pol 2008;79(2).

open access

Vol 79, No 2 (2008)
ARTICLES

Abstract

Abstract Objectives: The aim of our study was to assess the prognostic role of CA 125 regression during neoadjuvant chemotherapy (NAC) in patients with ovarian cancer (OC) or primary peritoneal serous carcinoma (PPSC) that underwent interval debulking surgery (IOC). Material and methods: Thirty one patients with advanced OC or PPSC (FIGO stage IIIC and IV) who underwent initial exploratory surgery, followed by NAC containing platinum analogs, have been analyzed, retrospectively. We have used a regression coefficient (RCA 125), which was calculated as following: log10 (CA 125 level measured after two cycles of NAC/ baseline CA 125) for statistical analysis. The median value of RCA 125 reached -0.788 and has been used to dichotomize. Optimal IOC has been performed in 67.74% (21/31) patients, suboptimal in 25.81% (8/31) patients and 6.45% (2/31) of patients did not undergo IOC due to the progression of the disease. Results: We have noted significant correspondence between time to progression and RCA 125 in univariate analysis, which we have also confirmed in multivariate analysis (HR 0.27; 95%CI, 0.15-0.96; p=0.0118). Similarly, we have observed significant relationship between overall survival, RCA 125 and extension IOC in univariate analysis. Multivariate analysis confirmed that RCA 125 was independent prognostic factor, HR-0.18 (95%CI, 0.07-0.56; p=0.004). In case of patients with high RCA 125, a greater rate of optimal debulking cytoreduction (p=0.0278, U=50.0) has been observed. Conclusions: RCA 125 after two courses of NAC appears to be an important prognostic factor in patients with OC or PPSC, who underwent IOC. High RCA125 during NAC seems to be a good predictive factor in order to achieve optimal IOC.

Abstract

Abstract Objectives: The aim of our study was to assess the prognostic role of CA 125 regression during neoadjuvant chemotherapy (NAC) in patients with ovarian cancer (OC) or primary peritoneal serous carcinoma (PPSC) that underwent interval debulking surgery (IOC). Material and methods: Thirty one patients with advanced OC or PPSC (FIGO stage IIIC and IV) who underwent initial exploratory surgery, followed by NAC containing platinum analogs, have been analyzed, retrospectively. We have used a regression coefficient (RCA 125), which was calculated as following: log10 (CA 125 level measured after two cycles of NAC/ baseline CA 125) for statistical analysis. The median value of RCA 125 reached -0.788 and has been used to dichotomize. Optimal IOC has been performed in 67.74% (21/31) patients, suboptimal in 25.81% (8/31) patients and 6.45% (2/31) of patients did not undergo IOC due to the progression of the disease. Results: We have noted significant correspondence between time to progression and RCA 125 in univariate analysis, which we have also confirmed in multivariate analysis (HR 0.27; 95%CI, 0.15-0.96; p=0.0118). Similarly, we have observed significant relationship between overall survival, RCA 125 and extension IOC in univariate analysis. Multivariate analysis confirmed that RCA 125 was independent prognostic factor, HR-0.18 (95%CI, 0.07-0.56; p=0.004). In case of patients with high RCA 125, a greater rate of optimal debulking cytoreduction (p=0.0278, U=50.0) has been observed. Conclusions: RCA 125 after two courses of NAC appears to be an important prognostic factor in patients with OC or PPSC, who underwent IOC. High RCA125 during NAC seems to be a good predictive factor in order to achieve optimal IOC.
Get Citation

Keywords

ovarian cancer - CA125, ovarian cancer - chemotherapy, chemotherapy - neoadjuvant therapy, gynecological surgical procedures - interval surgical cytoreduction

About this article
Title

CA 125 regression after two cycles of neoadjuvant chemiotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction

Journal

Ginekologia Polska

Issue

Vol 79, No 2 (2008)

Bibliographic record

Ginekol Pol 2008;79(2).

Keywords

ovarian cancer - CA125
ovarian cancer - chemotherapy
chemotherapy - neoadjuvant therapy
gynecological surgical procedures - interval surgical cytoreduction

Authors

Włodzimierz Baranowski
Cezary Szczylik
Małgorzata M. Jerzak
Gabriel B. Wcisło
Agnieszka Gąsowska-Bodnar

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl